Avoiding Antitrust Issues - - BioPharm International

ADVERTISEMENT

Avoiding Antitrust Issues


BioPharm International
Volume 1, Issue 8

46. Federal Trade Commission v Mylan Laboratories, 62 FSupp 2d 25 (DDC 1999).

47. US Department of Justice and Federal Trade Commission. Antitrust Guidelines for the Licensing of Intellectual Property (IP Antitrust Guidelines). Washington, D.C. 1995, April 6. Available at: http:// http://www.usdoj.gov/atr/public/guidelines/ipguide.htm.

Thomas J. Horton, J.D., is an antitrust and litigation partner at Thelen Reid & Priest LLP, 701 Eighth Street, NW, Washington, DC 20001, 202.508-4025, fax 202.508.4321,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here